PFE logo

Pfizer Inc.

PFE
Healthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50
Next Earnings Report
Feb 2, 2027
EPS est. $0.69 · Revenue est. $17.14B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Nov 20, 2025 (424B5). Possible dilution.

Upcoming Data Readouts (51)

Dec 2026
Est. completion
Invasive Fungal Disease
FungiScope - A Global Emerging Fungal Infection Registry
Dec 2026
Est. completion
P3Breast Cancer Recurrent
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Dec 2026
Est. completion
P1Healthy Participants
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Dec 2026
Est. completion
P2Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Dec 2026
Est. completion
P3Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Dec 2026
Est. completion
Breast Cancer
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Dec 2026
Est. completion
P2Lymphoma, Non-Hodgkin
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Dec 2026
Est. completion
P4Metastatic Urothelial Carcinoma
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Dec 2026
Est. completion
P1P2Recurrent Solid Tumor
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Jan 2027
Est. completion
P1P2Breast Cancer
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Jan 2027
Est. completion
P3Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Jan 2027
Est. completion
P2Stage III Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Mar 2027
Est. completion
Metastatic Breast Cancer
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311n=42,000
Mar 2027
Est. completion
P1P2Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Jun 2027
Est. completion
P1Carcinoma, Non-Small Cell Lung
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Jul 2027
Est. completion
P2Prostate Cancer
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Jul 2027
Est. completion
P2Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Jul 2027
Est. completion
P1Myelodysplastic Syndrome
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Jul 2027
Est. completion
P1Healthy
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
Aug 2027
Est. completion
P2Overweight
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

Awaiting Results (23)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P2
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308
Oct 2026
Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
NCT06647654
May 2026
P3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435
Mar 2026
P2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
Mar 2026
P1
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
NCT05266105
Feb 2026
P3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622
Dec 2025
P2
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT05170334
Oct 2025
LITMUS Imaging Study
NCT05479721
Sep 2025
P1
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
NCT04846478
Sep 2025
P1P2
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837

SEC Filings (74)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 20268-KMaterial eventDocumentIndex
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Oct 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 31, 2026N-PXDocumentIndex
Aug 13, 202613F-HRInstitutional holdings reportDocumentIndex
Aug 4, 202610-QQuarterly reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 16, 202611-KDocumentIndex
Jun 16, 202611-KDocumentIndex
May 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 12, 202613F-HRInstitutional holdings reportDocumentIndex
May 5, 2026S-8Employee stock planDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 27, 20268-KMaterial eventDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 12, 2026ARSAnnual report to holdersDocumentIndex
Mar 12, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 12, 2026DEF 14AProxy / shareholder voteDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 13, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 12, 202613F-HRInstitutional holdings reportDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Dec 16, 20258-KMaterial eventDocumentIndex
Nov 21, 20258-KMaterial eventDocumentIndex
Nov 20, 2025424B5Offering prospectusDocumentIndex
Nov 19, 2025FWPDocumentIndex
Nov 18, 2025424B3Offering prospectusDocumentIndex
Nov 13, 202513F-HRInstitutional holdings reportDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 4, 202510-QQuarterly reportDocumentIndex
Nov 4, 20258-KMaterial eventDocumentIndex
Aug 11, 202513F-HRInstitutional holdings reportDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex